N1048

Please Note: This trial is no longer enrolling new participants

N1048: A Phase II/III Trial of Neoadjuvant FOLFOX with Selective Use of Combined Modality Chemoradiation versus Preoperative Combined Modality Chemoradiation for Locally Advanced Rectal Cancer Patients Undergoing Low Anterior Resection with Total Mesorectal Excision

Challenges and solutions in the design and execution of the PROSPECT Phase II/III neoadjuvant rectal cancer trial (NCCTG N1048/Alliance)
Schrag D;Weiser M;Saltz L;Mamon H;Gollub M;Basch E;Venook A;Shi Q;
Patient-Reported Outcomes During and After Treatment for Locally Advanced Rectal Cancer in the PROSPECT Trial (Alliance N1048)
Basch E;Dueck AC;Mitchell SA;Mamon H;Weiser M;Saltz L;Gollub M;Rogak L;Ginos B;Mazza GL;Colgrove B;Chang G;Minasian L;Denicoff A;Thanarajasingam G;Musher B;George T;Venook A;Farma J;O'Reilly E;Meyerhardt JA;Shi Q;Schrag D;
Preoperative Treatment of Locally Advanced Rectal Cancer
Schrag D;Shi Q;Weiser MR;Gollub MJ;Saltz LB;Musher BL;Goldberg J;Al Baghdadi T;Goodman KA;McWilliams RR;Farma JM;George TJ;Kennecke HF;Shergill A;Montemurro M;Nelson GD;Colgrove B;Gordon V;Venook AP;O'Reilly EM;Meyerhardt JA;Dueck AC;Basch E;Chang GJ;Mamon HJ;
Which Treatment for Which Patient: Rectal Cancer Management After PROSPECT Trial
Felder S;Frakes J;George M;Rosen A;Sahin IH;